作者
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, KyungAh Im, Erica L Goodrich, Remo HM Furtado, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Deepak L Bhatt, Lawrence A Leiter, Darren K McGuire, John PH Wilding, Marc S Sabatine
发表日期
2019/4/23
来源
Circulation
卷号
139
期号
17
页码范围
2022-2031
出版商
Lippincott Williams & Wilkins
简介
Background
Glucagon-like peptide 1 receptor agonists (GLP1-RA) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) have emerged as 2 new classes of antihyperglycemic agents that also reduce cardiovascular risk. The relative benefits in patients with and without established atherosclerotic cardiovascular disease for different outcomes with these classes of drugs remain undefined.
Methods
We performed a systematic review and trial-level meta-analysis of GLP1-RA and SGLT2i cardiovascular outcomes trials using the PubMed and EMBASE databases (Excerpta Medica Database). The primary outcomes were the composite of myocardial infarction, stroke, and cardiovascular death (MACE); hospitalization for heart failure; and progression of kidney disease.
Results
In total, data from 8 trials and 77 242 patients, 42 920 (55.6%) in GLP1-RA trials, and 34 322 (44.4%) in SGLT2i trials, were included. Both …
学术搜索中的文章
TA Zelniker, SD Wiviott, I Raz, KA Im, EL Goodrich… - Circulation, 2019